General Statement of Disclosure:

CONSULTING FEES/HONORARIA: Novo Nordisk Inc.(MODEST), Milestone pharmaceuticals(MODEST) RESEARCH/RESEARCH GRANTS: Biocardia(SIGNIFICANT), CSL Behring LLC (CSLB)(SIGNIFICANT), LivaNova USA, Inc. (SIGNIFICANT), BIOTRONIK, INC.(SIGNIFICANT), Caladrius Biosciences(SIGNIFICANT), Abbott(SIGNIFICANT), TIMI Study Group and AstraZeneca(SIGNIFICANT), Medtronic, Inc(SIGNIFICANT), Medtronic, Inc.(MODEST), Evaheart, Inc(SIGNIFICANT), GE Healthcare Ltd. and its Affiliates(NONE), Novartis(SIGNIFICANT), Abbott Laboratories(SIGNIFICANT), Ablative Solutions, Inc(SIGNIFICANT), 3ive Labs, LLC(SIGNIFICANT), XyloCor Therapeutics, Inc.(SIGNIFICANT), Duke University/PCORI(SIGNIFICANT), NIH(SIGNIFICANT), nih(SIGNIFICANT), AHA(SIGNIFICANT), PCORI(SIGNIFICANT), NIH(SIGNIFICANT), NIH(SIGNIFICANT), DOD(SIGNIFICANT), NIH/Pittsburgh/RTI(SIGNIFICANT) OTHER FINANCIAL BENEFIT: DCRI(MODEST)

View Full Disclosure